Clinical Trial Update: Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance. [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating whether adding acetyl-L-carnitine to standard hepatitis C therapy with pegylated interferon alfa-2b plus ribavirin improves work perf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Acetyl-L-carnitine (N-acetyl-L-carnitine)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: University of Catania | Conditions: Quality of Life, Daily Activity | Phase 3 | Status: COMPLETED